Pharmafile Logo
Pharmafocus logo
Advanced Search
regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …

News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016
Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …

News
mr058666-web

Merck Q2 results beat analyst estimates

August 4, 2016
Medical Communications, Sales and Marketing Merck, financial results

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …

News
20160803-zika-dna-vaccine

NIH launches test of investigational human Zika vaccine

August 4, 2016
Research and Development Vaccine, Zika virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun the clinical …

News
fda2outsideweb

FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers

August 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech

The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer  Xiamen Origin Biotech, finding the …

News
adaptimmune_lab_scientists_growing_research_cells_jpg-web

Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

August 4, 2016
Research and Development Adaptimmune, T cell, oncology, t-cell

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …

News

American pharmacy adds 35 products to list of excluded drugs

August 4, 2016
Sales and Marketing Drug pricing, cvs health, excluded drugs, hyperinflationary

American pharmacy chain CVS Health has added 35 products to its list of excluded drugs and will not cover certain …

News
roche_south

Roche cuts ties with Inovio in hepatitis B development

August 3, 2016
Research and Development Inovio, Roche, hepatitis B

Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
celgene_1_02

Celgene’s Otezla approved for NHS use

August 3, 2016
Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News
novartis_building

Breakthrough therapy designation for Novartis in advanced breast cancer treatment

August 3, 2016
Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib

Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …

News
shire_image

Shire Q2 results outpace forecasts with 56% revenue growth

August 2, 2016
Research and Development, Sales and Marketing Baxalta, Shire, financial report

Shire has announced its fiscal results for Q2 2016, reporting a strong quarter with a 56% growth in total revenues …

News
pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

News

Landmark UK ruling as judge rules PrEP can be funded on NHS

August 2, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Judge, NHS, PrEP, UK, available, ruling

A London high court judge has ruled in favour of a challenge brought by the National Aids Trust to allow …

News

Joint Article on Hydrogen Peroxide Efficacy Published in Letters in Applied Microbiology

August 2, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wickham laboratories

Wickham Laboratories Ltd is pleased to announce the publication of a joint study with Bioquell on the efficacy of disinfection …

News
Press release
eisa0002

Evaluation of Eisai’s advanced thyroid cancer treatment blocked until 2018 in England

August 2, 2016
Manufacturing and Production, Sales and Marketing CDF, Eisai, Lenvima, NHS, NICE, lenvatinib, thyroid cancer

Following negotiations between the NHS, NICE and Japanese pharmaceutical company Eisai, differentiated thyroid cancer (RAI-R DTC) drug lenvima (levatinib) has …

News
biogen_austria_238

Success for Biogen, Ionis as spinal muscular atrophy drug performs in Phase III

August 2, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, phase III, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have announced that their spinal muscular atrophy treatment, nusinersen, met its primary endpoint at an interim …

News
pfizer_credit_flickr__ceiling

Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics

August 2, 2016
Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy

Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026